Feedback Share Discussion Threads

[21trader] 12/5/2015 09:37

blueball

How do you know FDA approval is not far away, are you a insider, do you know something others do not. Look at AGL they are still waiting far longer than anybody thought for their Rns on that not that it's damaging the price.

[sja123] 12/5/2015 09:24

Same report but different outlet...news getting around...

[sja123] 12/5/2015 09:20

"TexRAD can be integrated easily within existing hospital imaging systems
without the need for any hardware modifications and can also be accessed
via a pay-per-click service."

[the stigologist] 12/5/2015 09:17

and i doubt lawyers expert in FDA submissions come cheap

ask AGL how much they have spent over last 5 years

[the stigologist] 12/5/2015 09:16

nonsense and lies

they will only START application "soon"

FDA approval probably years away

"
The FDA approval application for the Group's software systems has been a more difficult process than anticipated due to the new procedures. We anticipate that the application will be made during the second quarter of 2015."

[blueball] 12/5/2015 08:13

This could easily double on FDA approval which is not far away.

[sja123] 12/5/2015 07:49

Sorry Stig...I had you unfiltered for a while but your back on filter this morning....what a load of c--p!

If you don't know that companies list on stock markets in order to raise finance and grow businesses then you really are naive IMO..

This is a very small company by market cap at present with a burgeoning global reach in terms of software and what it can do..

Of course, at some point, they will raise money...what's the problem...I invest in plenty of small companies that raise finance all the time and go on to grow bigger and better...

...and to draw attention to accounts at this stage of the company's growth is just stupid...there are companies on AIM with £400m mkt caps that don't make any money at all...YET!

The market looks forward and the future here is rather good IMO

All imo etc

[lr2] 11/5/2015 23:45

Blimey Stig, you've not been on ADVFN a year yet and you've clocked over 12 thousand posts. Geez what a gasbag and as gloomy as a graveyard on a wet Sunday.

I take it you're not a shareholder here, so what are you up to?

P.S. I don't think you comprehend the meaning of 'crony capitalists' either.

[the stigologist] 11/5/2015 22:59

Revenue - PATHETIC
Costs - GROWING
Losses - GROWING
FDA appoval - 'more difficult than anticipated'
oh dear problems ahead - 'a year of transition'

[the stigologist] 11/5/2015 22:57

Chairman's Statement

Revenue for the six month period was £229,000 (2013: non trading) and the loss after tax was £219,000. (2013: loss of £471,000). The loss before interest, tax and amortisation was £138,000 (2013: Loss £471,000). The cash balance at 30 November 2014 was £268,000, (2013: £696,000) which was after the payment of certain overdue creditors totalling £189,000 owed by CCI.

The FDA approval application for the Group's software systems has been a more difficult process than anticipated due to the new procedures. We anticipate that the application will be made during the second quarter of 2015.

The Group has invested in people over the period. Two new staff were appointed during the six months under review, with a further two joining before the year end to prepare the business for commercial sales of the products.

2015 is expected to be a year of transition for the Company as it moves from development to commercialisation with its TexRAD product.

Simon Barrell
Chairman

[the stigologist] 11/5/2015 22:52

watch out for the crony capitalists and pump and dump merchants in charge of this ramp to hit mug punters with a placing very soon

[blueball] 11/5/2015 21:38

hxxp://www.barchart.com/cheatsheet.php?sym=FDBK.LS

80% Buy.

[sja123] 11/5/2015 16:03

Just popped out for some lunch....nice surprise on return...shaping up well here IMO..:-)

[someuwin] 11/5/2015 15:35

Excellent news!

[daijavu] 11/5/2015 15:29

11 May 2015



Feedback plc

("Feedback" or the "Company")



Preliminary results from the Oxford Stone Group using TexRAD research software in the analysis of kidney stones



Feedback plc (AIM: FDBK), the medical imaging software company, previously announced on 13 April 2015 that it had signed a research agreement with the Oxford Stone Group at the University of Oxford & Oxford University Hospital NHS Trust ("Oxford"), UK to investigate the potential future clinical application of Feedback's TexRAD texture analysis software on computed tomography (CT) image data of patients with kidney stones.



The preliminary results from a 38 patient retrospective study so far are promising. Researchers at Oxford have demonstrated that TexRAD texture analysis could identify from pre-treatment CT scans which patients would have "successful" shockwave lithotripsy (SWL) therapy from those who would have "unsuccessful" therapy.



The research was led by Mr Ben Turney (Bernard Senior Clinical Researcher in Urology at the University of Oxford and Honorary Consultant Urological Surgeon) and carried out by Mr Daniel Stevens (Academic Clinical fellow in Urology at the University of Oxford).



Mr Ben Turney, a leading authority on stone disease in the UK, commented:



"Shock Wave Lithotripsy (SWL) is a well-established non-invasive surgical procedure for urolithiasis. However around 30-40% of patients do not achieve stone clearance and proceed to alternative treatments. We have demonstrated in this first preliminary study that TexRAD CT textural analysis appears to be an independent novel predictive biomarker for SWL success. TexRAD CT texture analysis may be a useful tool for risk-stratification and more accurately triaging those patients who will benefit from SWL. The next step is to undertake a prospective study to ascertain the clinical utility of this finding in a large population. Additionally, we shall explore other research questions such as assessing the stone composition and differentiate between actual stones and those conditions that mimic stone-like characteristics to increase diagnostic confidence and prevent unnecessary costly investigation and treatments."



Dr. Balaji Ganeshan, Chief Scientist & New Business Officer of the Company's subsidiaries TexRAD Ltd & Cambridge Computed Imaging Ltd commented:



"We are delighted with the positive results from the preliminary study within a few weeks of signing the research agreement with Mr Ben Turney and the team at Oxford. This is very encouraging news and provides an opportunity for Feedback Plc to develop a TexRAD based kidney stone software product dedicated to the management of kidney stone patients."



Mr Ben Turney and team have further submitted their preliminary results as an abstract for a possible presentation to the Challenges in Endourology meeting (hxxp://www.challenges-endourology.com) in Paris in June 2015.

[daijavu] 11/5/2015 15:24

Feedback plc (AIM: FDBK), the medical imaging software company, previously announced on 13 April 2015 that it had signed a research agreement with the Oxford Stone Group at the University of Oxford & Oxford University Hospital NHS Trust ("Oxford"), UK to investigate the potential future clinical application of Feedback's TexRAD texture analysis software on computed tomography (CT) image data of patients with kidney stones.

[blueball] 11/5/2015 15:15

Whats up ..?

[lr2] 11/5/2015 12:26

Autism & schizophrenia too.

[sja123] 11/5/2015 12:24

Also, love this paragraph from the same site...

"Our long term goal is to use TexRAD to support early diagnosis in cancer and other diseases and long term conditions such as dementia, and to enable early interventions and reduce disease progression"

....so, not just useful in all solid cancers....but already being trialed with kidney stones and possible use in dementia screening and diagnosis in the future...

Huge worldwide market in all these areas

All IMO etc